279 related articles for article (PubMed ID: 17699281)
1. Rituximab for idiopathic membranous nephropathy: who can benefit?
Ruggenenti P; Chiurchiu C; Abbate M; Perna A; Cravedi P; Bontempelli M; Remuzzi G
Clin J Am Soc Nephrol; 2006 Jul; 1(4):738-48. PubMed ID: 17699281
[TBL] [Abstract][Full Text] [Related]
2. [Efficiency of rituximab treatment for recurrence of membranous glomerulopathy after renal transplantation].
Wéclawiak H; Ribes D; Modesto A; Kamar N; Durand D; Rostaing L
Nephrol Ther; 2007 Apr; 3(2):65-8. PubMed ID: 17452303
[TBL] [Abstract][Full Text] [Related]
3. Low-dose angiotensin-converting-enzyme inhibitor captopril to reduce proteinuria in adult idiopathic membranous nephropathy: a prospective study of long-term treatment.
Rostoker G; Ben Maadi A; Remy P; Lang P; Lagrue G; Weil B
Nephrol Dial Transplant; 1995; 10(1):25-9. PubMed ID: 7724024
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of idiopathic membranous nephropathy. Is the anti-CD20 antibody rituximab a reasonable option?].
Busch M; Gerth J; Ott U; Schip A; Haufe CC; Gröne HJ; Wolf G
Med Klin (Munich); 2008 Jul; 103(7):519-24. PubMed ID: 18604487
[TBL] [Abstract][Full Text] [Related]
5. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy.
Cravedi P; Ruggenenti P; Sghirlanzoni MC; Remuzzi G
Clin J Am Soc Nephrol; 2007 Sep; 2(5):932-7. PubMed ID: 17702725
[TBL] [Abstract][Full Text] [Related]
6. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Willems HL; Wetzels JF
Nephrol Dial Transplant; 2008 Aug; 23(8):2546-51. PubMed ID: 18308774
[TBL] [Abstract][Full Text] [Related]
7. Treatment-related changes in urinary excretion of high and low molecular weight proteins in patients with idiopathic membranous nephropathy and renal insufficiency.
du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2006 Feb; 21(2):389-96. PubMed ID: 16234291
[TBL] [Abstract][Full Text] [Related]
8. Focal segmental glomerulosclerosis is not a sufficient predictor of renal outcome in patients with membranous nephropathy.
Heeringa SF; Branten AJ; Deegens JK; Steenbergen E; Wetzels JF
Nephrol Dial Transplant; 2007 Aug; 22(8):2201-7. PubMed ID: 17442739
[TBL] [Abstract][Full Text] [Related]
9. Rituximab treatment of idiopathic membranous nephropathy.
Fervenza FC; Cosio FG; Erickson SB; Specks U; Herzenberg AM; Dillon JJ; Leung N; Cohen IM; Wochos DN; Bergstralh E; Hladunewich M; Cattran DC
Kidney Int; 2008 Jan; 73(1):117-25. PubMed ID: 17943078
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study.
Cravedi P; Sghirlanzoni MC; Marasà M; Salerno A; Remuzzi G; Ruggenenti P
Am J Nephrol; 2011; 33(5):461-8. PubMed ID: 21508634
[TBL] [Abstract][Full Text] [Related]
11. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria.
Li X; Lv R; He Q; Li H; Du X; Lin W; Li Q; He X; Wang S; Chen J
J Nephrol; 2008; 21(4):584-91. PubMed ID: 18651550
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive therapy with cyclophosphamide and prednisolone in severe idiopathic membranous nephropathy.
Kibriya MG; Tishkov I; Nikolov D
Nephrol Dial Transplant; 1994; 9(2):138-43. PubMed ID: 8190328
[TBL] [Abstract][Full Text] [Related]
13. Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety.
Yang S; Xie L; Xue W; Yin A; Lu W
Nephrology (Carlton); 2013 Sep; 18(9):615-22. PubMed ID: 23889815
[TBL] [Abstract][Full Text] [Related]
14. Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study.
Haas M; Mayer G; Wirnsberger G; Holzer H; Ratschek M; Neyer U; Neuweiler J; Kramar R; Schneider B; Breiteneder-Geleff S; Regele HM; Hörl WH; Kerjaschki D
Wien Klin Wochenschr; 2002 Feb; 114(4):143-7. PubMed ID: 12060980
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient.
Gallon L; Chhabra D
Am J Transplant; 2006 Dec; 6(12):3017-21. PubMed ID: 17294527
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in idiopathic membranous nephropathy: a one-year prospective study.
Ruggenenti P; Chiurchiu C; Brusegan V; Abbate M; Perna A; Filippi C; Remuzzi G
J Am Soc Nephrol; 2003 Jul; 14(7):1851-7. PubMed ID: 12819245
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Ormond Disease and Idiopathic Membranous Glomerulonephritis by using Rituximab.
Dedinská I; Svetlík D; Adamicova K; Machalekova K; Makovicky P; Jezikova A; Laca L; Miklusica J; Galajda P; Mokan M
Iran J Kidney Dis; 2016 Sep; 10(5):332-335. PubMed ID: 27721233
[TBL] [Abstract][Full Text] [Related]
18. Rituximab in idiopathic membranous nephropathy.
Ruggenenti P; Cravedi P; Chianca A; Perna A; Ruggiero B; Gaspari F; Rambaldi A; Marasà M; Remuzzi G
J Am Soc Nephrol; 2012 Aug; 23(8):1416-25. PubMed ID: 22822077
[TBL] [Abstract][Full Text] [Related]
19. Idiopathic membranous nephropathy: diagnosis and treatment.
Fervenza FC; Sethi S; Specks U
Clin J Am Soc Nephrol; 2008 May; 3(3):905-19. PubMed ID: 18235148
[TBL] [Abstract][Full Text] [Related]
20. Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Steenbergen EJ; Wetzels JF
Nephrol Dial Transplant; 2008 Oct; 23(10):3160-5. PubMed ID: 18403431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]